Shemesh Shay 4
4 · Nuvectis Pharma, Inc. · Filed Sep 2, 2022
Insider Transaction Report
Form 4
Shemesh Shay
Chief Dev. & Ops. Officer
Transactions
- Purchase
Common Stock
2022-09-01$8.07/sh+1,530$12,347→ 1,244,441 total - Purchase
Common Stock
2022-08-31$8.07/sh+1,476$11,911→ 1,242,911 total
Footnotes (3)
- [F1]Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.05 to $8.10. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
- [F2]Includes 48,399 shares of restricted stock and 60,000 restricted stock units.
- [F3]Reflects the weighted average purchase price. The range of prices for the shares purchased was $7.85 to $8.17. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.